オカノ　テルオ   Okano Teruo   岡野　光夫    所属   医学研究科 医学研究科 (医学部医学科をご参照ください)    職種   評議員
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Allogeneic mesenchymal stem cell sheet therapy: A new frontier in drug delivery systems.
掲載誌名	正式名：Journal of controlled release : official journal of the Controlled Release Society 略　 称：J Control Release ISSNコード：18734995/01683659
掲載区分	国外
巻・号・頁	330,pp.696-704
著者・共著者	KIM Kyungsook†*, BOU-GHANNAM Sophia, KAMEISHI Sumako, OKA Masatoshi, GRAINGER David W., OKANO Teruo*
担当区分	最終著者,責任著者
発行年月	2020/12/19
概要	The evolution of drug discovery exploded in the early 20th century with the advent of critical scientific advancements in organic chemistry, chemical analysis, and purification. Early drug generations focused largely on symptom control and pain management, effective targets for small-molecule drugs. Recently, the attention in drug discovery has shifted to pursuit of radical cures. Cell therapy presents the ideal attributes of a promising new drug, targeting specific tissues based on chemotactic cues and modulating secretion of instructive regenerative molecules in response to dynamic signaling from disease environments. To actuate the therapeutic potential of cell therapy toward worldwide clinical use, cell delivery methods that can effectively localize and engraft mesenchymal stem cells (MSCs) with high disease-site fidelity and enable dynamic MSC bioactive function are paramount. In this review, we discuss the evolution of cell therapies with a focus on stem cell advantages, as well as the limitations to these therapies. This review aims to introduce cell sheet technology as a breakthrough cell therapy with demonstrated therapeutic success across indications for heart, liver, and kidney tissue regeneration. Opportunities and anticipated clinical impacts of cell sheet technology using MSCs are discussed.
DOI	10.1016/j.jconrel.2020.12.028
PMID	33347942